These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3853967)

  • 1. [Effect on human complement of blastolysin and the glycopeptide (MDP and GMDP) and carbohydrate fragments of peptidoglycans].
    Kozlov LV; Rostovtseva LI; Lomaka TS; Sutovskaia NS; Sorokina IB
    Bioorg Khim; 1985 Nov; 11(11):1510-8. PubMed ID: 3853967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Binding of activated C3b component with complement effector].
    Kozlov LV; Rostovtseva LI; Lomaka TS; Sutovskaia NS
    Bioorg Khim; 1985 Jun; 11(6):762-8. PubMed ID: 3849970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative study of the immunological properties of peptidoglycans of different origins].
    Zakharova NS; Shepeleva IB; Kalina NG; Britsina MV; Elkina SI; Andronova TM; Ermolova EV
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jan; (1):52-5. PubMed ID: 1858472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibition of formation of complement C5-convertase].
    Kozlov LV; Lebedeva TV
    Bioorg Khim; 1998 May; 24(5):350-5. PubMed ID: 9661788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the human complement cascade by bacterial cell walls, peptidoglycans, water-soluble peptidoglycan components, and synthetic muramylpeptides--studies on active components and structural requirements.
    Kawasaki A; Takada H; Kotani S; Inai S; Nagaki K; Matsumoto M; Yokogawa K; Kawata S; Kusumoto S; Shiba T
    Microbiol Immunol; 1987; 31(6):551-69. PubMed ID: 3670125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Isolation and structure of the active component of the antitumor agent blastolysin].
    Bezrukov MV; Andronova TM; Reshetova OS; Mal'kova VP; Sorokina IB
    Bioorg Khim; 1987 Mar; 13(3):386-94. PubMed ID: 3593429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Structure-functional study of glycosaminylmuramoyl peptides. The effect of chemical modification of N-acetylglucosaminyl-N-acetylmuramoyldipeptide on its immunomodulating properties in vivo and in vitro].
    Meshcheriakova EA; Gur'ianova SV; Makarov EA; Andronova TM; Ivanov VT
    Bioorg Khim; 1991 Sep; 17(9):1157-65. PubMed ID: 1807252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of binding of MDP, a synthetic immunoadjuvant, to anti-peptidoglycan antibodies.
    Audibert F; Heymer B; Gros C; Schleifer KH; Seidl PH; Chedid L
    J Immunol; 1978 Oct; 121(4):1219-22. PubMed ID: 701793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A mechanism of human complement activation by immunostimulators from the bacterial cell wall].
    Kozlov LV; Zinchenko AA; Soliakov LS; Sizoĭ MN; Ishchenko AM
    Bioorg Khim; 1983 Aug; 9(8):1047-55. PubMed ID: 6680304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muramylpeptides augment expression of Ia-antigens on mouse macrophages.
    Nesmeyanov VA; Khaidukov SV; Komaleva RL; Andronova TM; Ivanov VT
    Biomed Sci; 1990 Feb; 1(2):151-4. PubMed ID: 2102779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and antitumor activities of quinonyl-N-acetylmuramyldipeptides.
    Azuma I; Yamawaki M; Uemiya M; Saiki I; Tanio Y; Kobayashi S; Fukuda T; Imada I; Yamamura Y
    Gan; 1979 Dec; 70(6):847-8. PubMed ID: 535688
    [No Abstract]   [Full Text] [Related]  

  • 13. GMDP augments antitumor action of the CP/TNFalpha combination in vivo.
    Petrova EE; Simonova MA; Komaleva RL; Britsina MV; Andronova TM; Nesmeyanov VA; Valyakina TI
    Biomed Pharmacother; 2010 Apr; 64(4):240-8. PubMed ID: 19932583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in purine metabolism in the macrophages of mice exposed to a new synthetic analog of muramyl dipeptide].
    Umanskiĭ VIu; Tarakhovskiĭ AM; Andronova TM
    Biull Eksp Biol Med; 1985 Jun; 99(6):685-7. PubMed ID: 2990603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
    Isenman DE; Podack ER; Cooper NR
    J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Increase of non-specific resistance to infection by synthetic adjuvants].
    Parant M; Chedid L
    C R Seances Soc Biol Fil; 1979; 173(2):201-12. PubMed ID: 159749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of C5 convertase activity by properdin, factors B and H.
    Weiler JM
    Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
    [No Abstract]   [Full Text] [Related]  

  • 18. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Macrophage activation by blastolysin].
    Sorokina IB; Khasman EL; Gor'kova NP; Uchitel' IIa
    Biull Eksp Biol Med; 1980 Apr; 89(4):449-52. PubMed ID: 7388160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synthesis and protective activity of beta-glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine with alkylalicyclic and arylaliphatic aglycons].
    Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
    Bioorg Khim; 2005; 31(6):637-44. PubMed ID: 16363137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.